SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 7/28/2016 2:41:25 AM - Followers: 706 - Board type: Free - Posts Today: 1

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Insider Financial Publishes New Research On Three Promising Biotechs 07/16/2016 08:00:00 AM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:52:11 PM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:50:06 PM
CTIX News: Current Report Filing (8-k) 07/14/2016 08:11:43 AM
CTIX News: Statement of Changes in Beneficial Ownership (4) 07/11/2016 01:03:04 PM
PostSubject
#155690  Sticky Note Risk vs Volatility - I've been quietly watching BioHedge 07/26/16 12:34:09 AM
#155456  Sticky Note Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For wild4ctix 07/21/16 07:15:58 AM
#155327  Sticky Note Cellceutix advancing as a mid stage biopharmaceutical company. BooDog 07/19/16 07:31:34 AM
#155230  Sticky Note Some Due Diligence on B-UP sox040713 07/18/16 12:53:34 PM
#151674  Sticky Note An ever quickening pace of achievement.... rmzport 06/15/16 09:36:03 PM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#155797   That will happen one morning when we "Longs" vip1999 07/28/16 02:41:25 AM
#155796   It's going to take something nobody is expecting TheDane 07/27/16 09:21:39 PM
#155795   :-D ;-) TheDane 07/27/16 09:18:32 PM
#155794   I expected a big recovery after the lawsuit septmike09 07/27/16 08:53:30 PM
#155791   Would you go as far as to say BigKahuna 07/27/16 07:23:48 PM
#155788   The company never actively moved to the pinks. KarinCA 07/27/16 06:43:14 PM
#155787   " We are still on the otc and F1ash 07/27/16 06:39:45 PM
#155786   FINRA short sales of CTIX AlanC 07/27/16 06:35:18 PM
#155784   It could be something as simple as traders KarinCA 07/27/16 06:15:56 PM
#155783   Karen, You've put a lot of work into TheBunny 07/27/16 06:10:26 PM
#155782   In the world of nonsensical posts, that one Waverunner1 07/27/16 05:46:10 PM
#155781   It doesn't even make sense for Leo to KarinCA 07/27/16 05:44:09 PM
#155780   Once Aspire "sells" for Leo, do they give sox040713 07/27/16 05:40:47 PM
#155779   Bunny, you're smarter than that, Leo's beneficial ownership rule_rationale 07/27/16 05:24:36 PM
#155778   Would you go as far as to say cascott 07/27/16 05:16:35 PM
#155777   Actually, if you look at early 2015 you'll KarinCA 07/27/16 05:15:10 PM
#155776   Leo gets around Form 4 through 'trades' through TheBunny 07/27/16 04:49:58 PM
#155775   Well it's may be a little bit tougher septmike09 07/27/16 04:25:34 PM
#155774   I don't see any Form 4 for insider sox040713 07/27/16 04:15:00 PM
#155773   Problem is: No matter how much investors buy, TheBunny 07/27/16 04:07:19 PM
#155772   FDA Calls for More Restrictions on Fluoroquinolone Use incubus-now 07/27/16 03:28:46 PM
#155771   Good enough for you? septmike09 07/27/16 03:17:31 PM
#155769   I just finished buying 18,000 new shares throughout septmike09 07/27/16 02:50:03 PM
#155768   well i guess my name is No one govorchin 07/27/16 02:47:30 PM
#155766   I got out with a 200% profit today BIzzy 07/27/16 02:38:31 PM
#155760   FDA Drug Safety Communication: FDA updates warnings for sox040713 07/27/16 12:35:33 PM
#155759   Good. announce the progress. no follow govorchin 07/27/16 11:52:39 AM
#155758   MX Still have to wait for the K report Echo20 Echo20 07/27/16 11:01:08 AM
#155757   Gov Maybe a cure. Echo20 Echo20 07/27/16 10:58:22 AM
#155756   don't worry. we have been assured that govorchin 07/27/16 10:19:22 AM
#155754   yet another crappppppy day of price action. MXAMDUD 07/27/16 09:51:56 AM
#155753   Only sticky worthy if the hedge fund put iclight 07/27/16 05:59:53 AM
#155752   Edit: I see you found my explanation, so BigKahuna 07/27/16 02:58:37 AM
#155751   To use the short sales volume numbers for loanranger 07/27/16 02:49:00 AM
#155750   Yes, correct, according to the February 10, BigKahuna 07/27/16 02:48:17 AM
#155749   I forgot to send this out back in djs7 07/26/16 11:55:47 PM
#155748   Hi "BigKahuna" Tke heart, here in Jacksonville RJFL 07/26/16 11:02:50 PM
#155747   BigKahuna, The Kevetrin Ovarian 1B djs7 07/26/16 10:53:06 PM
#155746   I was actually surprised by the interview answers, KarinCA 07/26/16 09:30:41 PM
#155745   How so? All I'm saying is when daily BigKahuna 07/26/16 09:26:42 PM
#155744   Thank you for taking the time to compile F1ash 07/26/16 09:22:11 PM
#155743   Sounds like you read that out of a scottsmith 07/26/16 09:19:37 PM
#155742   The K Phase 1 finished months ago. We BigKahuna 07/26/16 09:19:10 PM
#155741   They on occasion have significance. They are only BigKahuna 07/26/16 09:17:10 PM
#155740   Bk How long now has the extended phase 1 Echo20 07/26/16 08:59:23 PM
#155739   So you attribute meaning to Alan's numbers? scottsmith 07/26/16 08:51:37 PM
#155738   Actually, low volume with very low daily short BigKahuna 07/26/16 08:18:37 PM
#155737   I think we are all going to end tombrady12nh 07/26/16 07:43:23 PM
#155736   Confirmation there's no buying interest, correct Alan? scottsmith 07/26/16 07:40:07 PM
#155735   Thanks Hound, you are correct may be time AlanC 07/26/16 07:32:37 PM
PostSubject